高甘油三酯血症遗传学研究进展

Recently, mendelian randomization data based on large cohort strongly suggest that hypertriglyceridemia (HTG) causes atherosclerotic cardiovascular disease , and so Triglyceride (TG) level-lowering treatment in HTG is now more strongly recommended to address the cardiovascular residual risk (CRR) than has been the case in published guidelines. With development of high-throughput?Sequencing thechonogy, Genome-wide association study (GWAS), Exome sequencing, epigenome-wide association studies(EWAS) and RNA sequencing have identified several novel common and rare variants, microRNA, LncRNA, DNA DNA methylation involving in abnormal TG clearance regulation,resulting in HTG. These research may led to innovative lipid target therapies for reducing e cardiovascular residual risk. We conduct a review to discussed the progression in this area.